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Summary: Nine patients with refractory partial seizures 
were evaluated in a pilot study of a new anticonvulsant 
compound, zonisamide ( 1,2-benzisoxazole-3-methane- 
sulfonamide; CI-912). Cognitive functioning was evalu- 
ated prior to treatment with zonisamide and repeated 
after 12 and 24 weeks of treatment with zonisamide. At 
minimum steady-state plasma concentrations >30 p,g/ml, 
zonisamide appeared to  affect specific cognitive func- 
tions such as  acquisition and consolidation of new infor- 
mation. Previously learned material, such as  vocabulary, 
and psychomotor performance were not affected. Verbal 
learning was affected, while visual-perceptual learning 
was unimpaired. These cognitive effects were observed 
in the absence of the usual clinical signs and symptoms of 
toxicity. A linear relationship was found between impair- 
ment of cognitive abilities and the minimum plasma con- 
centration ( r  = -0.73; p < 0.05). Findings also suggest 
the development of tolerance to  the adverse cognitive ef- 
fects. Key Words: Antiepileptic drugs-Cognition-Epi- 
lepsy- Neuropsychology- Zonisamide. 
The results of initial clinical trials have indicated 
that zonisamide ( 1,2-benzisoxazole-3-methanesul- 
fonamide; CI-912) may be effective in controlling 
partial seizures in humans (Sackellares et al., 1985; 
Wilensky et al., 1985). The anticonvulsant proper- 
ties of zonisamide were discovered through exten- 
sive testing of a variety of sulfonamide compounds 
(Masuda et al., 1980). Anticonvulsant properties of 
zonisamide have been demonstrated in several an- 
imal models, including maximal electroshock sei- 
zures, maximal pentylenetetrazol-induced seizures, 
and kindling (Masuda et al., 1980; Kamei et al., 
1981). The compound was shown to suppress focal 
spiking and spread of secondary generalized sei- 
zures in experimental animals (Ito et al., 1980). To- 
gether these works indicated that the anticonvul- 
sant profile of zonisamide was similar to that of 
phenytoin or carbamazepine. 
Masuda and co-workers (1979) studied the rela- 
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tionship between the plasma concentrations of zo- 
nisamide and anticonvulsant effects and impaired 
motor function in animals. Based on comparison 
with phenytoin, phenobarbital, and carbamazepine 
in these animal paradigms, the authors predicted 
that zonisamide would be effective clinically at 
plasma concentrations between 10 and 70 pg/ml. 
We previously described the single- and multiple- 
dose pharmacokinetics of zonisamide in patients 
receiving other antiepileptic drugs and reported 
preliminary evidence of the safety and efficacy of 
zonisamide in controlling medically refractory par- 
tial seizures in humans (Wagner et al., 1984; Sack- 
ellares et al., 1985). We found that in most patients, 
seizure frequency was reduced after substituting 
zonisamide for a standard antiepileptic drug. Dose- 
related, reversible central nervous system and gas- 
trointestinal side effects were observed, but most 
patients tolerated doses between 5.2 and 12.5 mg/ 
kg/day. Clinically significant antiepileptic effects 
were observed with plasma concentrations between 
15 and 20 kg/ml. Signs of clinical toxicity appeared 
to occur primarily when plasma concentrations ex- 
ceeded 40 kg/ml. 
A number of investigators have demonstrated 
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effects of antiepileptic drugs on cognitive func- 
tions (Matthews et al., 1975; Macleod et al., 1978; 
Thompson and Trimble 1980; Giordani et al., 1983). 
However, Trimble (198 1) has emphasized difficulty 
of separating antiepileptic drug effects on memory 
from the effects of seizures on learning and mem- 
ory. The cognitive side effects, moreover, might 
vary from one drug to another. Both Trimble and 
Thompson have argued for the careful measure- 
ment of behavior that is in direct relation to a spe- 
cific anticonvulsant compound. 
In the present study, we evaluated the effects of 
zonisamide on neuropsychological performance. 
Several aspects of behavior were measured to de- 
termine those abilities that tend to be vulnerable to 
drug effects as well as those that are more resistant 
to drug effects. Measures were chosen to reflect at- 
tention, concentration, sustained effort, personal 
and current information, verbal and visual-percep- 
tual learning, and immediate as well as delayed re- 
call of learned materials. 
METHODS 
Six men and five women of nonchildbearing po- 
tential entered this study. All patients were be- 
tween 19 and 50 years of age and had at least four 
partial seizures per month in spite of therapeutic 
plasma levels of two or three standard antiepileptic 
drugs. Patients with more than four generalized 
tonic-clonic seizures in the three months prior to 
the study were excluded. Patients with other signif- 
icant medical or psychiatric illnesses, with pro- 
gressive neurologic disorders, or those with a his- 
tory of status epilepticus were not eligible for this 
study. Informed written consent was obtained in 
each case. 
On entering the study, complete neurologic and 
general physical examinations, electrocardiogram, 
EEG, complete blood count, blood chemistry pro- 
file, plasma anticonvulsant levels, and urinalysis 
were obtained for each patient. Seizures were clas- 
sified according to the Revised International Classi- 
fication of Epileptic Seizures (Dreifuss et a]. , 198 1). 
One patient withdrew from the study before re- 
ceiving zonisamide and another patient was with- 
drawn by the investigator before completing all in- 
tended neuropsychological evaluations. This latter 
individual was withdrawn because of an abrupt in- 
crease in seizure activity. The nine patients com- 
pleting the clinical trial are included in the present 
report. The protocol employed in the clinical trial 
has been reported previously (Sackellares et al., 
1985). A summary of the study protocol is pre- 
sented in Table 1. 
TABLE 1. Sirmmury of experimental protocol 
Study phase Treatment Duration 
~ 
I .  Eligibility 
2. Baseline 
3.  Neuropsychological 
examination 








(session 3)  
6. Outpatient follow- 
7. Neuropsychological 
Two or three standard 
antiepileptic drugs 
8 weeks 
Single-dose kinetic study 12 weeks 
( 1  week), multiple-dose 
study ( 1  week), 
withdrawal of one 
baseline drug (-10 
days), continuation of 
zonisamide treatment 
12 weeks 
The study design included an 8-week baseline pe- 
riod during which each patient continued receiving 
either two or three standard antiepileptic drugs. 
These included phenytoin, phenobarbital, carbarn- 
azepine, primidone, and valproic acid. Details con- 
cerning individual doses and other clinical informa- 
tion have been provided by us in an earlier report 
(Sackellares et al., 1985). Following the baseline 
period, a single-dose pharmacokinetic study was 
performed. After completion of this pharmacoki- 
netic study, zonisamide was administered orally 
every 12 h. The initial dose for each patient was 
based on single-dose kinetic parameters calculated 
for that patient. On the 8th day of zonisamide treat- 
ment, each patient was admitted to the University 
of Michigan Clinical Research Center for - 10 days. 
One baseline antiepileptic drug was withdrawn and 
blood was sampled each day and later analyzed for 
all anticonvulsant drugs. Doses of zonisamide were 
adjusted to achieve a plasma concentration of 
15-40 pg/ml (or reduced, when necessary, to elimi- 
nate side effects). Once the plasma concentration 
of the drug withdrawn fell to ~ 1 5 %  of the initial 
level, the patient was discharged from the hospital 
and evaluated weekly for 4 weeks, then every 2 
weeks for the remainder of the 12-week treatment. 
Clinical and laboratory examinations were identical 
to those done during the baseline period. Following 
the initial drug withdrawal, no further drug was 
eliminated. 
Neuropsychological examinations were adminis- 
tered at the end of the 8-week pre-zonisamide base- 
line period (session I ) ,  and at the end of the 12th 
week of zonisamide treatment (session 2). Patients 
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were then continued in a follow-on study of zonisa- 
mide and were again evaluated with these neuro- 
psychological procedures at the end of 3 months 
into the follow-on period (session 3). All psycho- 
metric tasks were administered by trained neuro- 
psychological technicians. The technicians were 
not informed about drug or other clinical status of 
the patients except as  required for safe clinical 
management of the individual. 
The neuropsychological tests used in this study 
are listed and described in Table 2 .  The specific be- 
havioral tasks were chosen because of their estab- 
lished validity and reliability, including construct 
and face validity. When possible, tests with alterna- 
tive forms were used to minimize practice effects. 
Psychological tests for which the effects of prac- 
tices are fairly well understood also were em- 
ployed. For example, the Wechsler Memory Scale 
(WMS) was selected because of its alternative 
forms. The  Wechsler Adult Intelligence Scale 
(WAIS-R) was employed, because of its extensive 
use in studies with test-retest designs (Matarazzo, 
1974). Other tasks were chosen because they were 
easily standardized in administration. 
RESULTS 
The WMS yields a normalized, age-corrected 
memory quotient (MQ) which represents the com- 
bination of performance on the  various subscales 
which make up this instrument. Figure 1 presents 
the change in MQ that occurred for each patient be- 
tween the end of the baseline period and the end of 
the first 12-week zonisamide treatment period. 
Over this 12-week interval between test sessions, a 
substantial decline (up to 25% in some cases) in 
MQ was observed in every patient (mean change = 
Figure 2 illustrates the change in MQ that oc- 
curred between the second test session, performed 
after 12 weeks of zonisamide therapy, and the third 
test session, performed after 24 weeks of zonisa- 
mide therapy. 
In contrast to the first treatment period, the de- 
cline in MQ substantially receded for each patient 
at the time of this third testing. There was a move- 
ment in scores to within an average of five points 
from the original average MQ for the group of pa- 
tients under study (mean change between sessions 
2 and 3 = 10.1). 
The average MQ score for each test session is 
presented in Figure 3. 
The overall mean MQ for session 2 was signifi- 
cantly different from the mean MQ at baseline (p < 
0.001). Not only was there a change in average M Q  
between the sessions, but the mean plasma level for 
zonisamide was higher (but not significantly dif- 
ferent) in session 2 (31.2 pg/ml) than in session 3 
- 15.1). 
TABLE 2.  List and brief clescription ~~nc~ul-opsyrliologicNI instriimeiits employed 
Test instrument Description 
I .  Wechsler Memory Scale (WMS) (Wechsler. 1945) 
2. Wechsler Adult Intelligence Scale-Revised (WAIS-R), 
selected subtests (Wechsler. 1981) 
3. Reaction Time (RT)-Simple and Choice 
4. Grip Strength (Boll, 1981) 
5. Finger Tapping (Boll, 1981) 
6. Rod-and-Frame (Witkin et al., 1974) 
7. Grooved Peg Board 
A standardized and commercially available test of attention, learning. 
and memory. The score (MU) is a summary of performance on 
seven subtests. 
The Vocabulary subtest of the WAIS-R consists of words presented in 
increasing level of difficulty for the patient to define. Arithmetic is 
a series of arithmetic problems of varying levels of difficulty. Digit 
Symbol is a psychomotor task in which the person must translate 
numbers to symbols in a timed format. 
A Lafayette Instruments model 63014 multichoice Reaction Timer was 
used. Simple RT consists of subject responding to a red cue light as 
quickly as possible by pressing a response key with the dominant 
index finger. Twenty trials were administered, with subject’s score 
the mean in milliseconds over the last 10 trials. The choice 
procedure consisted of 30 trials with subject being asked to respond 
only to trials in which a red stimulus cue appeared. “Error” trials 
were interspersed at set intervals. Subject’s score was the average 
RT over the 10 test trials. A “warning” white cue light preceded the 
stimulus light by I s on all trials. 
measure the individual’s strength of grip (in kg pressure) for each 
hand. 
A standardized procedure was used to quantitate the person’s speed 
of oscillation of the index finger of each hand (measured in tapshin) .  
The apparatus yields a score, in degrees error from true vertical, of 
the patient’s ability to set a target rod to true vertical. 
Yields average time (in s) to place a set number of pegs in a standard 
test board. 
A standard, commercially available dynamometer was used to 
























S .  BERENT ET A L .  
- 
- 
O h  I 
I 
1 2 3 4 5 6 7 8 9  
INDIVIDUAL OBSERVATIONS 
FIG. 1. Change in Wechsler Memory Scale memory quo- 
tient (WMS-MQ) for each patient between session 1 (base- 
line) and session 2 (end of 12-week treatment period). 
(26.5 kg/ml). This observation suggests a relation- 
ship between plasma level of zonisamide and mea- 
sured cognitive function. Figure 4 reflects the very 
strong linear relationship that exists between the 
observed change in MQ and plasma levels of zoni- 
samide at the time of session 2 (Pearson r = - 0.73, 
p < 0.05). 
Interestingly, the very strong relationship be- 
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FIG. 2. Change in Wechsler Memory Scale memory quo- 
tient (WMS-MQ) for each patient between session 2 and ses- 
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FIG. 3. Average Wechsler Memory Scale memory quotient 
(WMS-MQ) for each test session. 
observed at the time of the second testing declined 
substantially by the time of the third test session. 
The relationship between the change in MQ be- 
tween session 3 and the baseline, session 1,  was r 
Table 3 summarizes performance on the behavior 
test measures and the various subtests of the WMS 
during each of the three test sessions. While initial 
learning on Verbal Paired Associate materials was 
affected at the time of the second test session (12th 
week of zonisamide therapy) (p < 0.05), visual- 
graphic learning was not. Orientation for personal 
and current information, as well as  to time and 
place, was also unaffected. Memory for passages of 
information that were read aloud to the patients 
(Logical Memory) also showed decline (p < 0.01), 
but alphabet recitation did not. In contrast to ob- 
servations of immediate recall tasks, where verbal 
learning alone showed a decline, visual-graphic as 
well as verbal performance showed a decline when 
the patient’s recall was delayed for 30 min after ini- 
tial learning. 
Statistically significant changes in overall MQ 
occurred between baseline testing and the test ses- 
sion performed after 12 weeks of zonisamide 
therapy. On the other hand, well-rehearsed and 
“crystallized” intellectual abilities, such as those 
reflected in the Vocabulary subtest of the WAIS-R, 
remained unaffected. Attention and psychomotor 
= -0.21 (p = NS). 
Epilepsiu, Vol. 28, No.  I ,  1987 


























FIG. 4. Scatter diagram of change in 
memory quotient (Ma) and corresponding 
plasma level of zonisamide for each patient 
in session 2. WMC, Wechsler Memory Scale. 
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and motor coordination tasks also showed no ef- 
fect, as reflected in tasks such as simple reaction 
time and time to complete a grooved peg board 
task. Perceptual orientation, as measured by the 
Rod-and-Frame test, and complex motor-symbolic 
learning, as reflected in the Digit Symbol subtest of 
cases reduced at the time of test sessions 2 and 3 in 
comparison with baseline measurements. For fur- 
ther information concerning seizure type and other 
clinical details, see our earlier report (Sackellares 
et al., 1985). 
the WAIS-R, remained relatively stable across test 
sessions. DISCUSSION 
It should be mentioned that all patients were 
judged to be free of seizure activity for at least 24 h 
prior to testing. Also, seizure frequency was in all 
The results of this pilot work suggest that zonisa- 
mide, in doses within the range tolerated clinically, 
affects specific types of cognitive abilities but not 
TABLE 3 .  Petfbrmance on behavioral tasks j b r  each test session 
Session I Session 2 t test" Session 3 f testa 
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7.3 (2.6) N S  
8.4 (2.1) NS 
3.3 (2.3) NS 
9.6 (11.4) NS 
322.7 (105.8) NS 
438.8 (137.6) NS 
43.7 (5.4) N S  
33.9 (10.6) N S  
89.8 (29.9) NS 
96.6 (10.4) NS 
8.8 (2.6) N S  
10.0 (1.8) NS 
13.2 (4.2) NS 
6.5 (2.6) NS 
7.9 (3.1) N S  
6.9 (2.1) NS 
a MQ, memory quotient; NS,  not significant. 
A f test for correlated samples was used for all comparisons and computed on a microcomputer with 
STATFAST 512.2. 
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others. These effects appear to be related linearly 
to plasma drug concentration. Acquisition of ver- 
bal material (verbal learning) was impaired, but 
learning of visual-graphic stimuli was unaffected by 
the drug. Previously learned material, such as vo- 
cabulary, and well-rehearsed acts (alphabet recita- 
tion) were unaffected, as was psychomotor ability 
(drawing of geometric shapes). The capacity to re- 
port the responses to test items was preserved in all 
cases. Immediate concentration and attention as 
well as  orientation to personal and external envi- 
ronment remained intact. After a delay of 30 min 
from initial practice, patients showed difficulty in 
recall of both verbal and visual-graphic task stim- 
uli. This finding suggests that the  effect on memory 
function is mechanistically distinct from the effect 
on initial acquisition of information, since only ini- 
tial acquisition of verbal items was impaired. 
The fact that impaired function was modality spe- 
cific rather than global is evidence against a global 
depression of cerebral function such as lethargy or 
motivation. Any hypothesis proposed to explain 
these results must account for the verbal learning 
and memory-specific attributes of the observed ef- 
fects and the lack of impact on more general be- 
haviors such as attention and motivation. 
The differences observed between test sessions 2 
and 3 suggest the development of tolerance to zoni- 
samide. However, the time course for the reduced 
effect of zonisamide on neuropsychological func- 
tion is unusually slow for the development of drug tol- 
erance. Because of the small number of observa- 
tions in the present work, further study will be re- 
quired to evaluate the hypothesis that improvement 
in behavioral function is a result of drug tolerance. 
If tolerance to the adverse cognitive effects of zoni- 
samide is confirmed, this finding would suggest that 
these adverse effects may be avoided by initiating 
treatment with lower doses. Higher doses may be 
used after tolerance to cognitive side effects de- 
velops. 
It is significant that patients and their families 
were unaware of a decline in ability in spite of rela- 
tively large changes in memory and learning ca- 
pacity. Since measurable adverse effects on cogni- 
tion may occur in the absence of clinical symptoms, 
patients receiving zonisamide should be monitored 
for  changes in mental s ta tus ,  especially when 
plasma drug levels are >30 kg/ml. A formal psy- 
chometric examination with a test such as  the 
WMS would be useful for early identification of 
cognitive impairment. Formal psychometric testing 
may be helpful in distinguishing adverse effects of 
zonisamide from other causes of impaired menta- 
tion such as drowsiness, lethargy, or depression. 
If comprehensive neuropsychological testing is 
not available, special attention should be paid to 
changes in the specific areas of mental ability such 
as learning and memory. 
Traditionally, the upper limit of the usual “thera- 
peutic range” of plasma level for an antiepileptic 
drug is determined by the level at which clinical 
signs or symptoms of adverse effects are observed. 
The results of this study suggest that, for some an- 
tiepileptic drugs, significant adverse effects may 
occur which are not detectable by the patient or by 
the bedside neurological examination. For drugs 
such as zonisamide, the upper limit of the thera- 
peutic range may be defined more precisely as the 
plasma level at which measurable changes in cogni- 
tive abilities are observed. In the present work, 
measurable cognitive effects surfaced at plasma 
levels above 30 kg/ml. Anticonvulsant effects were 
noted to occur below this level (see Sackellares et 
al., 1985). Although earlier animal studies had indi- 
cated that toxicity would occur well above 30 Fgiml 
(Masuda et al., 1979), there are individual differ- 
ences in response that need further elucidation. 
Cognitive as well as clinical side effects have been 
observed at plasma drug concentrations below this 
point (Sackellares et al., 1985). 
The use of objective, quantifiable, and standard- 
ized psychometric techniques in the present work 
allowed for a detailed description of the kinds of 
cognitive abilities that changed as a function of 
plasma concentrations of zonisamide. In large part, 
the clarity of these results in the presence of a rela- 
tively small number of observations is due to the 
homogeneity of baseline scores that were earned by 
the patients in the study. Nevertheless, the results 
demonstrate the usefulness of psychometrics in ap- 
plication to research in the development of new 
medications. 
The generalizability of these findings is limited 
by a number of considerations in addition to those 
already mentioned. Conclusions must be tentative 
since the size of the study was small. Patients were 
taking medications other than zonisamide and these 
may have potentiated the effects on cognition. No 
control group was employed. In short, these results 
seem clearly to reveal a strong relationship be- 
tween drug plasma concentrations of zonisamide 
and specific cognitive side effects. Any conclusions 
about absolute cause and effect, however, will re- 
quire further study. 
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RESUMEN 
En un estudio piloto realizado para valorar la eficacia de la 
zonisamida (1,2-Bencisoxazol-metanosulfonamida [CI-9121). u n  
nuevo compuesto anticonvulsivo. se han evaluado unos 9 pa- 
cientes con ataques parciales refractarios al tratamiento. Se de- 
termino la capacidad cognitiva anterior al tratamiento y se re- 
pitio 12 y 24 semanas despues del tratamiento con zonisamida. 
Con concentraciones plasmaticas minimas estables per encima 
de  30 mcgiml, la zonisamida afecto las funciones cognitives 
especificas tales como la adquisicion y consolidacion de nueva 
informacion. El material aprendido previamente, tal como el vo- 
cabulario, y las funciones psicomotoras no se afectaron. El 
aprendizaje verbal se modifico mientras que el aprendizaje 
visuo-perfectivo no se modific6. Estos efectos cognitivos se ob- 
servaron en ausencia de 10s habitudes signos y sintomas clinicos 
de toxicidad. Se encontro una relacion lineal entre la alteracion 
de las posibilidades cognitivas y la concentracion plasmatica 
minima (r = -0.73, p < 0.05). Estos hallazgos tambien sugieren 
el desarrollo de una tolerancia a 10s efectos cognitivos adversos. 
(A. Portera-Sinchez, Mudrid) 
ZUSAMMENFASSUNG 
9 Patienten mit rezidivierenden Partial-Anfallen wurden in 
einer Pilotstudie mit einer neuen antiepileptischen SubstanL: 
Zonisamide untersucht. Die kognitiven Funktionen wurden vor 
der Behandlung mit Zonisamide gepruft und nach 12 und 24 
Therapiewochen mit Zonisamide wiederholt. Bei einem Min- 
destplasmaspiegel von 30 mcgiml schien Zonisamide spezifische 
kognitive Fahigkeiten wie Aufnahme und Speicherung neuer In- 
formationen zu beeintrichtigen. Vorher gelernte Inhalte wie 
sprachliche und psychomotorische Fertigkeiten wurden nicht 
beeinflufit. Verbales Lernen war ebenfalls betroffen. wihrend 
visuell, perzeptives Lernen nicht verschlechtert war. Diese 
Beeintrachtigung kognitiver Funktionen wurde bei fehlenden 
klinischen Intoxikationszeichen beobachtet. Eine lineare Bezie- 
hung zwischen Verschlechterung kognitiver Fahigkeiten und 
Mindest-Plasmaspiegel konnte hergestellt werden (r = - 0,73; p 
< 0,OS). Allerdings lassen die Ergebnisse auch auf eine Gewoh- 
nung an diese unerwunschten Nebenwirkungen schlieRen. 
(C. G. Lipinski, HeidelbergiNecX~ir~erniin6) 
Epilepsia, V o / .  28, N o .  I .  I987 
